NASDAQ: MLTXMoonlake Immunotherapeutics Stock
$22.16+2.95 (+15.36%)
Updated Jun 22, 2026
MoonLake Immunotherapeutics shares are trading... find out Why MLTX Price Moved with a free WallStreetZen account
Why Price MovedMLTX Price
$22.16
Fair Value Price
$4.01
Market Cap
$1.63B
52 Week Low
$5.95
52 Week High
$62.75
P/E
-5.73x
P/B
6.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$259.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.58
Operating Cash Flow
-$224M
Beta
0.67
Next Earnings
Aug 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MLTX Overview
MoonLake Immunotherapeutics develops medicines for immunologic diseases, including inflammatory skin and joint diseases. It focuses on enhancing its novel tri-specific Nanobody Sonelokimab (SLK) product, an inhibitor to treat multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. The company is conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MLTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MLTX
Ranked#466 of 467
Ranked#466 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.92 | A | |
| $51.35 | A | |
| $2.16 | A |
Be the first to know about important MLTX news, forecast changes, insider trades & much more!
MLTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MLTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MLTX ($22.16) is overvalued by 451.96% relative to our estimate of its Fair Value price of $4.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MLTX ($22.16) is not significantly undervalued (451.96%) relative to our estimate of its Fair Value price of $4.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MLTX due diligence checks available for Premium users.
Valuation
MLTX fair value
Fair Value of MLTX stock based on Discounted Cash Flow (DCF)
Price
$22.16
Fair Value
$4.01
Overvalued by
451.96%
MLTX ($22.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MLTX ($22.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MLTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.73x
Industry
15.1x
Market
7.94x
MLTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.42x
Industry
5.1x
MLTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MLTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$69.7M
Profit Margin
0%
MLTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$400.4M
Liabilities
$146.4M
Debt to equity
0.58
MLTX's short-term assets ($396.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MLTX's short-term assets ($396.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MLTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MLTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$66.3M
Investing
$98.0k
Financing
$30.6M
MLTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MLTX vs Biotech Stocks
Moonlake Immunotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.